Table 1. Human brain samples information.

PATIENT ID	CLINICAL DIAGNOSIS	ANATOMO-PATHOLOGICAL DIAGNOSIS	GENDER	AGE	TIME POSTMORTEM (hours)
CT1	Control	NFT II + alpha synuclein in olfactory bulb	Male	64	10
CT2	Control	AgD I	Male	83	13
CT3	Control	Cerebral metastasis from lung cancer + NFTI-II	Female	56	14
CT4	Control	Spine thrombosis D + cerebellar ictus +bulb, NFT III	Female	86	4
CT5	Control	iLBD Braak 1, NFT I-II, SVD	Male	78	6
CT6	Control	Minimum AgD I, with patched gliosis	Male	76	11,5
SPD1	PD	LBD Braak 4, ARP I B	Male	71	5
SPD2	PD	LBD Braak 4 + NFT Braak II	Male	77	12
SPD3	PD	LBD Braak 4, ARP II/A, discreet CAA, SVD	Male	88	15
SPD4	PD	LBD 4-5 + ARP IIA	Female	83	4
SPD5	PD	LBD Braak 5 + ARP III B + CAA mod	Male	74	8
SPD6	PD	LBD Braak 5 + AgD	Male	81	5

CT= control individuals, SPD= sporadic PD patients LBD: Lewy body disease, stages based on Braak et al. (2003): 1-6. ARP: Alzheimer-type pathology: classification of the neurofibrillary pathology NFT based on Braak et al., (2006) (I-VI) and the neuritic plaques based on CERAD criteria (A-C), CAA amyloid angiopathy. PMD: postmortem delay (in hours). AgD: Argyrophilic grain Disease, SVD Small Vessel Disease.